Summary
Eli Lilly & Company (LLY) filed an 8-K on April 21, 2008, to report its financial results for the first quarter ended March 31, 2008. The report highlights the company's performance, providing both GAAP and non-GAAP financial measures. A key aspect of this filing is the detailed explanation of significant non-GAAP adjustments used to present a clearer view of ongoing operational performance. These adjustments include items like restructuring charges, in-process R&D costs from acquisitions and in-licensing deals, asset impairments, and tax benefits from IRS audit resolutions. The company emphasizes that these non-GAAP figures are intended to help investors understand operational trends and make meaningful period-over-period comparisons, but should be considered alongside, not as a substitute for, GAAP measures. The filing also includes financial expectations for the full year 2008, presented on both GAAP and adjusted bases.
Key Highlights
- 1Reporting of Q1 2008 financial results and full-year 2008 financial expectations.
- 2Use of non-GAAP financial measures to provide a clearer view of ongoing operational performance.
- 3Significant non-GAAP adjustments in Q1 2008 include a tax benefit from IRS audit resolution and charges related to the termination of the AIR Insulin program.
- 4Non-GAAP adjustments in prior periods (2007) include restructuring charges, in-process R&D for acquisitions (ICOS, Hypnion, Ivy), and charges related to Zyprexa product liability.
- 5Company believes non-GAAP information aids in evaluating ongoing operations and identifying trends.
- 6Investors are advised to consider non-GAAP measures in addition to, not as a substitute for, GAAP measures.
- 7The filing incorporates a press release dated April 21, 2008, detailing these results and expectations.